Focus on Human Papillomavirus (HPV) in the immunocompromised host and in non cervical cancers Friday 13 February 2009, 0900 16:30 Holme Building, Science Rd, University of Sydney 9:00 9:15 Welcome Prof. Tania Sorrell (University of Sydney) 9:15 9:30 Overview of Workshop Prof. Raina MacIntyre (University of New South Wales) 9:30 9:55 Epidemiology of HPV in the Australian Context Dr. Julia Brotherton (National Centre for Immunisation Research & Surveillance) (20 mins talk, 5 min questions) 9:55 10:20 Advances in HPV vaccination Prof. Suzanne Garland (Royal Women s Hospital) (20 mins talk, 5 min questions) Symposium/Workshop Human Papillomavirus (HPV) in the immunocompromised host 10:20 10:45 Oncological Perspectives on HPV related non cervical cancers A/Prof Eva Segelov (20 mins talk 5min questions) 10:45 11:00 Morning tea 11:00 11:45 HPV vaccination research in immunocompromised Dr Jane Leong (Merck/CSL) (30 mins talk, 15 min questions) 11:45 12:30 HPV vaccination research in immunocompromised Dr Su peing Ng & Dr Scott Preiss (GSK) (30 min talk s, 15 min question) 12:30 12:55 Neonatal HPV Prof. Robert Booy (National Centre for Immunisation Research & Surveillance) (25 mins talk, 5 min questions)
12:55 13:30 Lunch 13:30 15:15 HPV clinical research in Immunosuppressed in Australia Prof. Raina MacIntyre (15 min) Dr. Helen Marshall (15 min) Dr. Jim Buttery (15 min) Dr. Joe Sasadeusz (15 min) Dr. Claire Vajdic (15 min) Dr. Fiona Mackie (15 min) Discussion and research directions (15 min) 15:15 15:35 Modelling of HPV vaccination of boys Dr. David Philp (15 mins talk, 5 min questions) 15:35 15:50 Afternoon tea 15:50 16:30 Discussion panel vaccination of boys and reaching at risk target groups. Supported by: To register please contact Michelle Sams e : m.sams@unsw.edu.au t : 02 9385 3811
Professor Tania Sorrell MBBS (Adelaide), MD (Adelaide), FRACP is Professor of Clinical Infectious Diseases and Director of the Centre for Infectious Diseases and Microbiology, Director of CIDM Biomed, and a member of the executive of CIDM Public Health. She is a graduate of the University of Adelaide, with an MD in Clinical Immunology. She was appointed Professor of Clinical Infectious Diseases at the University of Sydney in 1988. Professor Raina MacIntyre is Head of the School of Public Health and Community Medicine at UNSW and professor of infectious diseases epidemiology. She runs a highly strategic research program spanning epidemiology, vaccinology, mathematical modelling, public health and clinical trials in infectious diseases. Her research is supported by NHMRC and ARC grants, and she has received international recognition by way of a major award, the Sir Henry Wellcome Medal and Prize, from the US military in 2007 for her work on bioterrorism. She has also won the Australian Society for Infectious Diseases Award for Advanced Research in Infectious Diseases. She is best known for research in the detailed understanding of the transmission dynamics and prevention of infectious diseases, particularly respiratory pathogens such as influenza, tuberculosis and other vaccine preventable infections. She has a particular interest in adult vaccination with a focus on the elderly and immunosuppressed. Dr Julia Brotherton B Med (Hons), MPH (Hons), Grad Dip App Epi, FAFPHM is a public health physician from Melbourne, Australia. She is a medical graduate from the University of Newcastle, NSW, and has a Masters degree in Public Health from the University of Sydney. She completed her speciality training in Public Health through the NSW Public Health Officers Training Program. For the past 5 years Julia has been involved in research and policy development informing the implementation and evaluation of HPV vaccination programs in Australia. Whilst working as a senior research fellow at the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), Julia served as a member of, and technical writer for, the HPV Working Party of the Australian Technical Advisory Group on Immunisation. Julia has recently commenced working at the Victorian Cytology Service as the epidemiologist for the National HPV Vaccination Program Register and Victorian Cervical Cytology Register. She is currently undertaking a PhD on HPV vaccination in Australia. Professor Suzanne Garland is a clinical microbiologist and sexual health physician, with a particular interest and expertise in infectious diseases as they pertain to reproductive health and the neonate. She also has key research interest in cervical cancer and the role of human papillomaviruses (HPV) being involved in defining the molecular epidemiology of HPV in cervical dysplasia, cervical cancer, and the healthy population within Australia, as well as the chief investigator of a study defining the prevalence of HPV genotypes in urban, rural, indigenous and non indigenous Australian women pre HPV vaccine rollout. She is an Advisor to WHO with a specific role of in roll out of prophylactic HPV vaccines to resource poor countries, as well as, development of international standards for HPV DNA and serological assays. She is the past and inaugural President of the newly formed society, AOGIN (Asian Oceania Research Organization on Genital Infection and Neoplasia), which brings together clinicians and scientists within the Asian and Oceania regions and whose work is related to genital infections and neoplasia Associate Professor Eva Segelov MBBS (Hons 1, PhD, FRACP) is Associate Professor of Medicine at St Vincent s Clinical School, UNSW. She is a medical oncologist specialising in GI cancer with a particular interest in Upper GI cancer and HPV carcinogenesis. With Professor MacIntyre, she has collaborated on projects looking at vaccination in immunosuppressed populations and is interested in long term prevention not only of cervical but other HPV related cancers (anus, head and neck and oesophagus). Dr Jane Leong is the Medical Director at CSL Biotherapies. Following graduation from the University of Melbourne, Jane trained in internal medicine and family medicine before receiving her fellowship from the Royal Australian College of General Practitioners and completing a Masters in Business Administration at the Melbourne Business School. She was in general practice before joining the pharmaceutical industry. She has had over 10 years industry experience including positions of Associate Medical Director and Head of Regulatory Affairs and Medical Information and Pharmacovigilance at GlaxoSmithKline Australia. As Medical Director at CSL Biotherapies, Jane is responsible for various medical functions including global postmarketing pharmacovigilance for vaccines manufactured at the Parkville site and marketed around the world. She has recently been involved in launching GARDASIL for both Australia and New Zealand national HPV vaccination programs.
Dr Scott Preiss is the medical scientist for Cervarix working in the medical department at GlaxoSmithKline. Scott has a PhD from the University of Melbourne on HIV Nucleic Acid Vaccines. His scholarly activities have focused on vaccines, virology and the mechanisms pathogens use to avoid the innate and acquired immune systems. He was invited to Latrobe University to present lectures on these topics. Previously he worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL) where he published research on the Hepatitis B virus and Toll Like Receptors. He has also been involved with the Australian/ Thailand HIV Vaccine Consortium which sponsored an HIV vaccine to phase I/II clinical trials. Professor Robert Booy is Head of the Clinical Research team at the National Centre for Immunisation Research and Surveillance (NCIRS) where he joined in March, 2005. He is a medical graduate of the University of Queensland (1984) and trained in Paediatrics at the Royal Children's Hospital, Brisbane. Professor Booy has held a range of positions in the UK including Professor of Child Health with the University of London; Lecturer in Paediatric Infectious Diseases at St Mary s Hospital, London; Research Fellow with the University of Oxford; and was the recipient of a Wellcome training fellowship in epidemiology focusing on genetic factors important in meningococcal disease. Professor Booy s research interests extend from understanding the genetic basis of susceptibility to, and severity of, infectious diseases especially influenza and invasive disease caused by encapsulated organisms), the clinical, publichealth, social and economic burden of these diseases (acutely and over the long term) and means by which to prevent or control serious infections through vaccines, drugs and non pharmaceutical measures. Dr Helen Marshall is the Director of the Paediatric Trials Unit, a multidisciplinary research group involved in immunisation research, at the Women s and Children s Hospital and a Senior Lecturer in the Discipline of Paediatrics and Discipline of Public Health at the University of Adelaide. Dr Marshall is a medical graduate who has completed a Master in Public Health degree and the Advanced Vaccinology Course at the Pasteur Merieux Institute in France. Dr Marshall has been an Investigator for over 40 Phase I IV clinical trials in experimental vaccines and immunisation research. Her current research interests include varicella, pertussis, meningococcal and HPV immunisation and translation of vaccine research into public health policy. Dr Jim Buttery is a paediatric infectious diseases physician, actively involved in immunisation policy and research since 1995. His major interests are clinical vaccinology, vaccine safety and newborn infections. He is based at Monash Medical Centre and the Royal Children's Hospital as an infectious diseases paediatrician. He is the Director of SAEFVIC, (Surveillance of Adverse Events Following Immunisation), the first integrated vaccine safety service in Australia linking clinical services with adverse event surveillance. He is also the head of the Special Risk Program Leader of the NH&MRC Centre for Clinical Research Excellence in Child and Adolescent Immunisation and is a chief investigator on NHMRC grants of over $3.5 million. He holds a Master s degree in Evidence Based Health Care, and has submitted his MD thesis, relating to rotavirus infections in UK child care nurseries. He serves on the Pharmaceutical Benefits Advisory Committee, is a member of the Paediatric Medicines Advisory Group, and is the Clinical Expert for the National Medicines Policy Committee. Dr. Joe Sasadeusz is an infectious diseases physician primarily based at the Royal Melbourne Hospital with cross appointments at the Alfred Hospital and the Melbourne Sexual Health Centre in Melbourne Australia. He undertook his basic medical training at Monash University Melbourne which was followed by advanced training in general medicine then infectious diseases training in Melbourne. He then moved to the University of British Columbia in Vancouver Canada where he completed a Ph. D in the area of antiviral resistance. His background training is in medical virology and he has worked for several years in the area of infections in patients who have undergone stem cell transplantation Dr Claire Vajdic obtained a PhD in cancer epidemiology from the University of Sydney in 2002. That year she was awarded a NHMRC Postdoctoral Training Fellowship, which she undertook at the National Centre in HIV and Clinical Research, University of New South Wales (UNSW). Since 1996 she has examined the risk factors for cancer, including environmental, infectious and immunological determinants. In 2008 she was awarded a NHMRC Career Development Award, and a Cancer Institute NSW Career Development and Support Fellowship. Dr Vajdic is currently Team Leader of the Cancer Aetiology and Prevention Group, at the UNSW Cancer Research Centre.
Dr Fiona Mackie is a Senior Staff Specialist in Nephrology at Sydney Children s Hospital. She is the principal investigator on a CARG grant from Roche looking at immunogenicity and duration of immunity with HPV vaccine in children and adults with a kidney transplant ( Co investigators Professor R. McIntyre, Professor Bruce Pussell and Dr Sean Kennedy). Fiona was awarded a PhD from Sydney University in 2001 and trained in clinical nephrology at Stanford University, U.S.A., Royal Prince Alfred and Royal Alexandra Children s Hospitals. Dr David Philp is a Postdoctoral Fellow at the School of Public Health and Community Medicine at UNSW. Since 2005 he has been involved in mathematical modelling of transmissible diseases, especially human papillomavirus and pandemic influenza. His research contributed to the Australian Management Plan for Pandemic Influenza 2006, and CSL's submission to the Pharamaceutical Benefits Advisory Committee for the funding of Gardasil.